Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

Stealth BioTherapeutics to Report Full Year 2020 Financial Results on Tuesday, April 6, 2021


BOSTON, March 31, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report full year 2020 financial results on Tuesday, April 6, 2021, before the market opens.

Management will host a conference call at 8:30 am ET that day to discuss the financial results and provide a general business update. The call can be accessed by dialing (877)-407-0989 (domestic) or (201)-389-0921 (international) and referencing conference ID 13717131. A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/. A replay of the webcast will be archived on Stealth's website for 30 days following the event.

About Stealth

We are a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are also involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne and Becker muscular dystrophies and Friedreich's ataxia, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical stage candidate, SBT-272, for rare neurodegenerative disease indications following promising preclinical data in amyotrophic lateral sclerosis, or ALS. Our pipeline compounds include SBT-259, which we are evaluating for rare peripheral neuropathies, and the SBT-550 series of compounds, which we plan to evaluate for rare neurodegenerative and ophthalmic indications. We have optimized our discovery platform to identify novel mitochondria-targeted compounds, which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria. We have assembled a highly experienced management team, board of directors and group of scientific advisors to help us achieve our mission of leading mitochondrial medicine.

Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
[email protected] 

SOURCE Stealth BioTherapeutics Inc.


These press releases may also interest you

at 08:10
Skyflow, the data privacy vault company, has raised $30 million to extend its Series B funding. Khosla Ventures led the round, joined by prior investors Mouro Capital, Foundation Capital and Canvas Ventures. The investment follows revenue growth of...

at 08:10
NICE today announced that Triple Impact Connections, a veteran-owned BPO firm based in the United States, has selected the industry-leading NICE CXone platform to help drive great customer service and long-term value. With the move to CXone, Triple...

at 08:10
Edgewise Therapeutics, Inc. , a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology's Annual Scientific Session (ACC.24). EDG-7500 is a first-in-class...

at 08:10
The Board of MariaDB plc ("MariaDB" or the "Company") confirms that on March 26, 2024, it received an unsolicited non-binding indicative proposal from Progress Software Corp. ("Progress") to acquire the entire issued and to be issued share capital...

at 08:08
B&H is ready for the 2024 Great North American Solar Eclipse and has all the resources and equipment you need to get ready yourself. Less than a month away, the total solar eclipse is happening on Monday, April 8, 2024, and starts at 11:07AM PT. This...

at 08:07
Input 1, a leading digital billing and payment solution provider to the insurance industry, is thrilled to announce two new features designed to enhance the capabilities and services of their platform. These additions, Custom Credit Card Statement...



News published on and distributed by: